COMP <GO>
IAM vs FDMT // EV/EBITDA & P/E VALUATION
Iambic Therapeutics Inc. (NASDAQ) VS. 4D Molecular Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: IAM 0
— FDMT 2
■ METRIC PARITY
LAST: $14.28 (-3.38%) • MKT CAP: $676.9M
valuation
—
LAST: $12.78 (-1.16%) • MKT CAP: $706.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IAM VS. FDMT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IAM | FDMT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -28.30% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -15.53% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.17 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 5/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.3 | 44.1 | -5.85 | FDMT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $676.9M | $706.0M | -$29.1M | FDMT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IAM REV | FDMT REV | IAM GROSS % | FDMT GROSS % | IAM FCF | FDMT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $85.2M | — | — | — | -$109.6M |
| FY 2024 | — | $37.0K | — | — | — | -$138.4M |
| FY 2023 | — | $20.7M | — | — | — | -$75.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IAM // BETA —
FDMT // BETA —